Literature DB >> 3180352

Progressive hypoxemia limits left ventricular oxygen consumption and contractility.

K R Walley1, C J Becker, R A Hogan, K Teplinsky, L D Wood.   

Abstract

To study the cardiac effects of progressive hypoxemia, we measured the left ventricular end-systolic pressure-volume relation (ESPVR), myocardial oxygen consumption (MVO2), and myocardial oxygen delivery (MQO2) in eight thoracotomized dogs anesthetized with fentanyl and droperidol. We specifically looked for evidence of oxygen supply limitation of MVO2 and depressed contractility (altered ESPVR) during stepwise decreases in inspired oxygen fraction. We hypothesized that the reported relation between MVO2 and left ventricular pressure-volume area (PVA) may hold when inadequate MQO2 determines MVO2, which then may limit PVA, manifested partly as a change in the ESPVR. Initially, as arterial oxygen saturation was decreased from 95 +/- 3% to 64 +/- 14%, coronary blood flow increased so that MQO2 was maintained with no change in myocardial extraction ratio (ERm = MVO2/MQO2). During this first phase, lactate utilization, PVA, and ESPVR did not change. When oxygen saturation was further reduced, coronary blood flow rose no higher and ERm increased, but not enough to maintain MVO2. Lactate consumption decreased and ST segments rose, signaling a change from aerobic metabolism. MVO2 decrease was associated with a fall in PVA, which was due to a fall in blood pressure and a significant depression of the ESPVR. Specifically, the volume intercept of the ESPVR increased in all dogs (6.5-20.1 ml, p less than 0.0001), accounting for two thirds of the increase in end-systolic volume. The slope of the ESPVR decreased during hypoxia (13.3-6.1 mm Hg/ml, p less than 0.02), accounting for only one third of the observed increase in end-systolic volume. We believe that the evidence of anaerobic metabolism, the decrease in PVA, and the depression of the ESPVR demonstrates onset of oxygen supply limitation of MVO2. Our data are consistent with the hypothesis that limited MVO2 may limit PVA. The hypoxic volume intercept alteration of the ESPVR is different from changes in the slope of ESPVR seen with other interventions. This may be analogous to recent observations in isolated muscle that show hypoxic depression in contractility to be different from other interventions.

Entities:  

Mesh:

Year:  1988        PMID: 3180352     DOI: 10.1161/01.res.63.5.849

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Simulation study of the Hemopump as a cardiac assist device.

Authors:  X Li; J Bai; P He
Journal:  Med Biol Eng Comput       Date:  2002-05       Impact factor: 2.602

Review 2.  Regulation of myocardial oxygen delivery.

Authors:  B Schremmer; J F Dhainaut
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 3.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 4.  Cardiac efficiency.

Authors:  J D Schipke
Journal:  Basic Res Cardiol       Date:  1994 May-Jun       Impact factor: 17.165

5.  Left ventricular depression and pulmonary edema in rats after short-term normobaric hypoxia: effects of adrenergic blockade and reduced fluid load.

Authors:  Peter Appelt; Philipp Gabriel; Christian Bölter; Nicole Fiedler; Katrin Schierle; Aida Salameh; Beate Rassler
Journal:  Pflugers Arch       Date:  2021-09-12       Impact factor: 3.657

6.  Relaxin does not prevent development of hypoxia-induced pulmonary edema in rats.

Authors:  Ute Kowalleck; Mohamed A Abdalla Ahmed; Julia Koedel; Katrin Schierle; Aida Salameh; Beate Rassler
Journal:  Pflugers Arch       Date:  2022-07-02       Impact factor: 4.458

7.  Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic.

Authors:  Jason Boehme; Natacha Le Moan; Rebecca J Kameny; Alexandra Loucks; Michael J Johengen; Amy L Lesneski; Wenhui Gong; Brian D. Goudy; Tina Davis; Kevin Tanaka; Andrew Davis; Youping He; Janel Long-Boyle; Vijay Ivaturi; Jogarao V S Gobburu; Jonathan A Winger; Stephen P Cary; Sanjeev A Datar; Jeffrey R Fineman; Ana Krtolica; Emin Maltepe
Journal:  PLoS Biol       Date:  2018-10-18       Impact factor: 8.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.